Evaluation of molecular imaging of DNA synthesis for diagnosis, theraputic value and recurrent diagnosis of head and neck tumor

Evaluation of molecular imaging of DNA synthesis for diagnosis, theraputic value and recurrent diagnosis of head and neck tumor - 4'-[methyl-11C]thiotymidine(4DST)PET for head and neck carcinoma diagnosis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000006466

Enrollment

Registered

2011-10-04

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and neck carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Age:>20 years old at entry of this traial 2.Pathological diagnosis was squamous cell carcinoma 3.Patient who was planning of chemoradiation in primary lesion. 4.Completed the written informed consent.

Exclusion criteria

Exclusion criteria: 1.Pregnancy or lactating womem, or women with suspected pregnancy. 2.Patient with severe underlying disease having risk of liver dysfunction, renal dysfunction and any metabolic damage. 3.Just after surgery and/or trauma. 4.Poor controled diabetics. 5.Anaphylaxis of thiotymidine or tymidine. 6.Those who are determined as not appropriate for the study by physician in chief.

Design outcomes

Primary

Measure	Time frame
As a surrogate marker of pretreatment and theraputic evaluation, 4DST-PET could be superior than FDG-PET.	—

Countries

Japan

Contacts

Public ContactJyunkichi Yokoyama

Juntendo university hospital Department of Otorhinolaryngology

Outcome results